Project Grant R03AI192375
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$165K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award in the amount of $3,019,293 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports a prospective 5-year study to investigate the causes and mechanisms of Post-Treatment Lyme Disease Syndrome (PTLDS), a complex condition that lacks consensus on diagnosis and treatment. The study is being conducted by a multidisciplinary team of clinicians,...
This $382,500 five-year Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research supports research at Washington State University to study the functional and mechanistic aspects of the Lyme disease spirochete's genetic factors encoded on plasmid LP17. The key objectives are to: 1) Establish the importance of genes BBD21 and BBD22 for controlling the copy number of Borrelia burgdorferi plasmids and the...
The Project Grant award, with Federal Grant Award ID R41AI179571, is provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $300,000 award, effective July 17, 2024 through June 30, 2026, supports the development of a broad-spectrum prophylactic for tick-borne diseases, specifically Lyme disease and relapsing fever. The grantee, Planet Biotechnology Incorporated, will use a plant-based...
This Project Grant award of $461,375.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Yale University to systematically identify interactions between Lyme disease bacteria, Borrelia burgdorferi, and proteins from its tick vector, Ixodes scapularis. The goal is to develop a comprehensive database of these pathogen-vector interactions, which can inform strategies to block transmission or interrupt the...
This Project Grant award of $191,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Washington State University to study the mechanism of antigenic variation in the Lyme disease spirochete, Borrelia burgdorferi. The research aims to decipher the role of specific genetic factors in the expression and recombination of the VlsE surface protein, which is a key mechanism for immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $162,000.00 to The Johns Hopkins University to conduct research on how the spirochete Borrelia burgdorferi, the causative agent of Lyme disease, uses epidermal growth factor (EGF) as an environmental cue to coordinate its gene expression during the infection cycle. The research aims to characterize the binding of EGF...
The federal Project Grant award R01AI186279 of $1,663,244.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to characterize innate immune signaling pathways in the tick Ixodes scapularis. The project aims to improve understanding of immune signaling in ticks, which are vectors of Lyme and other emerging diseases, by combining cell culture-based methods with in vivo assays in...
The University of South Florida was awarded a $509,130 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to define the role of the BosR regulator in controlling virulence gene expression and the infectious cycle of the Lyme disease pathogen Borrelia burgdorferi. Key objectives include characterizing the BosR regulon, examining the regulation of BosR expression,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,933 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to L2 Diagnostics LLC, a for-profit biomedical research company based in Woodbridge, Connecticut. The project aims to develop a novel therapeutic using a secretory leukocyte protease inhibitor (SLPI) to mitigate Lyme arthritis and post-treatment Lyme disease syndrome. The award period runs from July 8, 2024 to June 30, 2026....
This $199,984 Project Grant awarded by the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to increase the fundamental understanding of the immune response to various Lyme disease antigens using bacterial outer membrane vesicles (OMVs) as a novel carrier system. The research objectives are to: 1) explore fusion proteins as a proof of concept to present full Borrelia burgdorferi (BB) antigens on OMVs, 2) determine the potential to express multiple BB antigen epitopes on...